But from a purely clinical standpoint, semaglutide is typically the better first choice for most patients seeking weight loss
Studies conducted on various cellular and animal models have demonstrated that both GIP and GLP-1 exert marked anti-apoptotic effects in pancreas (125127)
American Diabetes Association Professional Practice Committee, ElSayed NA, Aleppo G, et al
Once youve reached a steady dose, aiming for 0.5-1% of body weight loss per month is more practical than hoping for rapid early results
(Interestingly enough, the provider does not need to be enrolled in Medicare, but must not be on the Preclusion List.) How does the Bridge interact with Medicares existing GLP-1 coverage
The team at Transition handles prior authorization efforts for both medications as part of the program